Home > About Company > Advisory Board
Carl V. Hanson, Ph.D.

Carl V. Hanson, Ph.D., is the principal investigator on grants from NIH and the U.S. Army for the development and evaluation of HIV vaccines and the study of HIV virology, immunology, and serology. In 1994, Dr. Hanson was the first to observe that experimental AIDS vaccines based on laboratory-adapted HIV strains evoked little or no neutralizing antibodies to protect patients from infection, thereby overturning all previous work done worldwide on HIV vaccines. Dr. Hanson is also the first author of over 90 scientific publications and a reviewer for NIH and several prominent AIDS journals. Currently he serves as a faculty at University of California, Berkeley and head of the Retrovirus Diagnostics Section of the Viral and Rickettsial Disease Laboratory of the California Department of Health Services, Richmond, CA, which serves as California’s reference laboratory for HIV diagnostics.
For the past 15 years, Dr. Hanson has been collaborating closely with UBI to apply his state-of-the art neutralizing antibody assays to UBI’s HIV immunotherapy and vaccine development programs. In addition, Dr. Hanson is a reviewer for NIH and several prominent AIDS journals, and is Chairman of the “Neutralization Task Force” for the International AIDS Vaccine Initiative (IAVI). Dr. Hanson started his career in biomedical science and virology after he earned his Ph.D. in biophysics from Harvard University.

Connie L. Finstad, Ph.D.

Connie L. Finstad, Ph.D., was an investigator at the Memorial Sloan-Kettering Cancer Center in New York City, NY where she was one of the first to study monoclonal antibody therapy for human solid tumors. Dr. Finstad joined UBI in 1997 to manage our cancer immunotherapy project and became Executive Director of Preclinical and Clinical Affairs in 1998. During her service in UBI, she was also a co-investigator in National Institute of Allergy and Infectious Diseases (NIAID) on anti-host humanized monoclonal antibody, HIV-RC vaccine, and HIV-1 immunotherapy projects. Dr, Finstad has been granted multiple Small Business Innovation Research funds. Furthermore, as Director of Preclinical and Clinical Affairs of UBI, Dr. Finstad coordinated and supervised domestic and international preclinical and clinical trials for cancer and AIDS.
Dr. Finstad earned her Ph.D. from New York University and has over 50 publications and 9 patents in cancer immunotherapy and diagnosis. Dr. Finstad is one of the pioneers in cancer monoclonal antibody therapy.

Dr. Tzu-Chen Yen, Ph.D.

Dr. Yan, Ph.D., graduated from National Yang-Ming University, specializing in nuclear medicine, radioimmunoassay, molecular medicine, and biochemistry. Currently, Dr. Yan is the Director and professor in the nuclear medicine department at Chang Gung Medical University, the Director of and professor of molecular imaging center in Chang Gung Hospital, professor in Department of Chinese Medicine and Department of Biomedical Imaging and Radiological Sciences at Chang Gung Medical University, and professor in Electrical Engineering and Computer Science at National Tsing Hua University. She persuaded Chang Gung Medical Hospital to build a NTD $500 million Translational Bioimaging Center and conducted both educational training for center popularization and cooperative research for academic exchanges. This center has over 150 publications on PubMed with over 100 of them published in the past 5 years.

Dr. Shu-Fen Lo

Dr. Lo is a physician at Chang Gung Medical Hospital (Department of Rheumatology and Immunology) and a professor in College of Medicine of Chang Gung Medical University. She is honored in the field of autoimmune disease. Dr. Lo is a Director in Taiwan Rheumatology Association, Taiwanese Osteoporosis Association, Chinese Society of Immunology, and a Deputy Director in the Asia Pacific League of Associations for Rheumatology. In addition to her clinical achievements, Dr. Lo has published numerous papers about systemic lupus erythematosus and rheumatology. Dr. Lo graduated from the College of Medicine, National Taiwan University.

Jian-Tai Timothy Qui, Ph.D.

Jian-Tai Timothy Qui, Ph.D. is currently a physician at Chang Gung Memorial Hospital and an associate professor in College of Medicine at Chang Gung University, specializing in cancer immunology and virology. Dr. Qui received his M.D from National Yang-Ming University and his Ph.D. in Immunological Medicine from Johns Hopkins University in the US. Dr. Qui has dozens of publications in cancer field. He currently serves as the Chairperson of Gynecologic Oncology Research Center at Chang Gung Memorial Hospital, Chairperson of Asian Gynecologic Oncology Group, a consultant of Taiwan Center of Drug Evaluation, and a member of editing committee of Gynecologic Oncology, International Journal of Gynecologic Cancer and Chang Gung Medical Journal.

Wen-Chun Peng, Ph.D.

Wen-Chun (James) Peng, Ph.D. is the Vice President of R&D at United Biomedical, Asia (UBIA). He established the protein/antibody expression technology platform in mammalian cells and set up the screening platform for selecting high productivity cell lines. He also participated in the construction of cGMP protein drug pilot plant and assisted with setting up the GLP laboratory to support the development of UBI Asia’s innovative immunotherapy products. His team has accomplished numerous projects such as development of antibodies, biosimilar drugs, biomedical instruments, and human and animal vaccines. His team is also involved in and executes preclinical and clinical studies such as development of vaccines and antibodies for Alzheimer’s disease, AIDS, bird flu, and other infectious diseases.
Dr. Peng earned his Ph.D. in biomedical science from National Tsing Hua University, specializing in molecular virology and molecular biology.

Dr. Ming-Hsun Lee, Ph.D.

Dr. Ming-Hsun Lee holds a Bachelor of Medicine from Kaohsiung Medical College, and received his Master’s degree in Infectious Diseases from Imperial College, University of London, and Ph.D. in Microbiology from Queen Mary and Westfield College, University of London. Dr. Lee is a physician and specialized in infectious disease control and AIDS treatment with many publications in the area of infectious diseases. He was a member of Acute Neuron Syndrome Review Committee at Center of Disease Control, National Health Insurance Administration of Ministry of Health and Welfare (NHI), and a member of Health Review Committee at National Health Insurance Administration-Northern Division. He was also a Visiting Staff in Division of Infectious Diseases and General Medicine at Chang Gung University who has extensive clinical experience in infectious medicine. Currently, he is a Visiting Staff in Division of Infectious Diseases at Chang Gung Memorial Hospital.

Wei-Li Chen, Chief Pharmacist

Mr. Wei-Li Chen is specialized in management of clinical drug. He served as a Deputy Director of Pharmacy Department at Chang Gung Memorial Hospital, Linkou, a Pharmacist of Pharmacy Department at Taipei City Hospital, and a Director of Taiwan Clinical Pharmaceutical Association. Currently, he is a Supervisor of Tao Yuan Pharmacist Association, the committee member of Pharmaceutical Education Planning Board and Taiwan Pharmacist Association, and a Senior Engineer of Project Development Division in Medical Department, Formosa Plastics Group.